Hendrik Peter Scholl - 18 Mar 2026 Form 3 Insider Report for BELITE BIO, INC (BLTE)

Reporting relationship: Chief Medical Officer
Issuer ticker: BLTE
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 15:32:49 UTC
Next SEC filing: 23 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Hendrik Peter Scholl

Key filing fact

Hendrik Peter Scholl filed Form 3 for BELITE BIO, INC (BLTE) on 18 Mar 2026.

Key facts

This page summarizes Hendrik Peter Scholl's Form 3 filing for BELITE BIO, INC (BLTE).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 15:32.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002113223 Primary reporting owner

Scholl Hendrik Peter

Relationship: Chief Medical Officer
Address: GOTTHARDSTRASSE 26, ZUG, SWITZERLAND
Signature: /s/ Hendrik Peter Scholl
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLTE holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 35,000
Date: 18 Mar 2026
Ownership: By Bioptima Ltd.

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLTE holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: By Bioptima Ltd.
Underlying class: Ordinary Shares
Underlying amount: 100,000
Exercise price: $48.68
Footnotes: F1

BLTE holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: By Bioptima Ltd.
Underlying class: Ordinary Shares
Underlying amount: 75,000
Exercise price: $54.88
Footnotes: F2

BLTE holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: By Bioptima Ltd.
Underlying class: Ordinary Shares
Underlying amount: 40,000
Exercise price: $158.36
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option shall vest (i) as to 50,000 ordinary shares on the first anniversary of September 1, 2024, and (ii) as to 50,000 ordinary shares in 24 equal and continuous monthly installments for each full month following the first anniversary of September 1, 2024, subject to continued service to the Issuer on each such date.

Footnote F2

The option shall vest (i) as to 12,500 ordinary shares on September 1, 2025, and (ii) as to 62,500 ordinary shares in 30 equal and continuous monthly installments for each full month following September 1, 2025, subject to continued service to the Issuer on each such date.

Footnote F3

The option shall vest (i) as to 13,333 ordinary shares on January 9, 2027, (ii) as to 13,333 ordinary shares on January 9, 2028, and (iii) as to 13,334 ordinary shares on January 9, 2029.

SEC remarks

Exhibit 24 - Power of Attorney